SGMO vs. ATAI

In the year-to-date period, SGMO achieves a -57.06% return, which is significantly lower than ATAI's 7.52% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Sangamo Therapeutics, Inc. (SGMO) and Atai Life Sciences N.V. (ATAI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SGMO Sharpe Ratio is -0.15, which is higher than the ATAI Sharpe Ratio of -0.29. The chart below compares the historical Sharpe Ratios of SGMO and ATAI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SGMO nor ATAI has paid dividends to shareholders.

The maximum SGMO drawdown since its inception was -99.40%, roughly equal to the maximum ATAI drawdown of -94.77%. Use the drawdown chart below to compare losses from any high point for SGMO and ATAI. For additional features, visit the drawdowns tool.

Sangamo Therapeutics, Inc. (SGMO) has a higher volatility of 56.05% compared to Atai Life Sciences N.V. (ATAI) at 14.38%. This indicates that SGMO's price experiences larger fluctuations and is considered to be riskier than ATAI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Sangamo Therapeutics, Inc. and Atai Life Sciences N.V.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.